Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

@article{NeuschwanderTetri2015FarnesoidXN,
  title={Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.},
  author={Brent A Neuschwander-Tetri and Rohit Loomba and Arun J Sanyal and Joel E. Lavine and Mark L. Van Natta and Manal F. Abdelmalek and Naga Chalasani and Srinivasan Dasarathy and Anna Mae Diehl and Bilal Hameed and Kris V. Kowdley and Arthur Joseph McCullough and Norah A. Terrault and Jeanne M Clark and James A Tonascia and Elizabeth M. Brunt and David E Kleiner and Edward C Doo},
  journal={Lancet},
  year={2015},
  volume={385 9972},
  pages={956-65}
}
BACKGROUND The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal models of fatty liver disease. We assessed the efficacy of obeticholic acid in adult patients with non-alcoholic steatohepatitis. METHODS We did a multicentre, double-blind, placebo-controlled, parallel group, randomised clinical trial at medical centres in the USA in patients with non-cirrhotic, non… CONTINUE READING
Highly Influential
This paper has highly influenced 24 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 365 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Similar Papers

Loading similar papers…